Patient-derived xenograft models for the study of benign human neoplasms

Souza, Juliana Cristina de; Miguita, Lucyene; Gomez, Ricardo Santiago; Gomes, Carolina Cavaliéri

doi:10.1016/j.yexmp.2021.104630

Cited by 4 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To establish CGCG PDX model, 16 tumour fragments were cut with a PDX from case#2 caused suppuration and necrosis, mice were euthanized, and no data were recorded. The other animals were monitored for 56 days, except for case #4, which was monitored for 47 days.…”

Section: Patient-derived Xenograft (Pdx) Model Of Central Giant Cell ...mentioning

confidence: 99%

Central giant cell granulomas of the jaws stromal cells harbour mutations and have osteogenic differentiation capacity, in vivo and in vitro

Luiz

Souza

Bastos

et al. 2022

J Oral Pathology Medicine

Self Cite

View full text Add to dashboard Cite

Background: Central giant cell granulomas (CGCG) of the jaws are osteolytic lesions that may behave aggressively and respond poorly to surgery. Microscopically, in addition to giant cells, there is a mononuclear cell population composed of macrophage/ monocytic cells and spindle-shaped cells of mesenchymal origin. Seventy two percent of these tumours harbour mutually exclusive TRPV4, KRAS and FGFR1 mutations. We aimed to assess the mutational status of mononuclear and giant cells and the osteogenic potential of stromal cells in vitro and in vivo. Methods and Results:We screened CGCG for signature mutations and used lasercapture microdissection to demonstrate that the mutations are restricted to the mononuclear cells. Additionally, we established CGCG primary cell culture and observed that the cells retained the mutations throughout passages. By flow cytometry, we observed predominance of CD14 − CD51 − CD61 − cells, consistent with the expected profile for stromal cells. Considering the mesenchymal origin of stromal cells, we assessed the osteogenic differentiation potential of CGCG cells in culture by cytochemistry (von Kossa and alizarin red staining), alkaline phosphatase (ALP) activity assay and gene expression of osteogenic markers. CGCG cells presented self-capacity to increase ALP levels in a time-dependent manner and under osteogenic induction presented increasing number of calcium deposits, and overall higher expression of | 207 MIGUITA eT Al.

show abstract

Section: Patient-derived Xenograft (Pdx) Model Of Central Giant Cell ...mentioning

confidence: 99%

Central giant cell granulomas of the jaws stromal cells harbour mutations and have osteogenic differentiation capacity, in vivo and in vitro

Luiz

Souza

Bastos

et al. 2022

J Oral Pathology Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…The minimally processed tumour fragments of OM (n = 5) were obtained and subcutaneously implanted in mice to establish the patient-derived xenograft (PDX) model and obtained as described previously. 9,10 The fragments were collected 55 days after implantation into three 8-week-old male NUDE BALB/c mice. On this day, the size of the PDX tumour fragments was significantly smaller than at implantation.…”

Section: Patient-derived Xenograftmentioning

confidence: 99%

Angiogenesis in patient‐derived xenografts of odontogenic myxoma

Souza

Bastos

Pereira

et al. 2022

Int J Experimental Path

Self Cite

View full text Add to dashboard Cite

Previously, by employing 3D organotypic tissue culture and patient‐derived xenograft (PDX) model, oral myxoma response to a MAPK/MEK inhibitor was observed. Gross examination of the tumour fragments obtained after 55 days of PDX grafting revealed increased capsule vascularization. Microscopic analyses showed blood capillaries intermixed with myxoma cells, but the origin of these capillaries, from mice or humans, was not established. This study aimed to investigate whether the endothelial cells observed in the myxoma PDX model are derived from the mouse or from the primary human tumour. Immunohistochemistry was performed on five tumour fragments from the PDX of myxoma after 55 days of implantation in mice. Immunopositivity for antibodies against human (HLA‐ABC) and mouse (H2 Db/H2‐D1) major histocompatibility complex class I (MHCI) was assessed in the endothelial cells. The endothelial cells in the PDX fragments revealed a membrane staining for the human MHCI protein in the PDX tumour and adjacent connective tissue capsule, indicating that capillaries were derived from the human tumour fragment. Considering the probable human origin of the endothelial cells from capillary blood vessels in the myxoma PDX, we conclude that this PDX model is an interesting model to study myxoma angiogenesis.

show abstract

Organoids: approaches and utility in cancer research

Zhou

Feng

et al. 2023

Chinese Medical Journal

View full text Add to dashboard Cite

Organoids are three-dimensional cellular structures with self-organizing and self-differentiation capacities. They faithfully recapitulate structures and functions of in vivo organs as represented by functionality and microstructural definitions. Heterogeneity in in vitro disease modeling is one of the main reasons for anti-cancer therapy failures. Establishing a powerful model to represent tumor heterogeneity is crucial for elucidating tumor biology and developing effective therapeutic strategies. Tumor organoids can retain the original tumor heterogeneity and are commonly used to mimic the cancer microenvironment when co-cultured with fibroblasts and immune cells; therefore, considerable effort has been made recently to promote the use of this new technology from basic research to clinical studies in tumors. In combination with gene editing technology and microfluidic chip systems, engineered tumor organoids show promising abilities to recapitulate tumorigenesis and metastasis. In many studies, the responses of tumor organoids to various drugs have shown a positive correlation with patient responses. Owing to these consistent responses and personalized characteristics with patient data, tumor organoids show excellent potential for preclinical research. Here, we summarize the properties of different tumor models and review their current state and progress in tumor organoids. We further discuss the substantial challenges and prospects in the rapidly developing tumor organoid field.

show abstract

Patient-derived xenograft models for the study of benign human neoplasms

Cited by 4 publications

References 80 publications

Central giant cell granulomas of the jaws stromal cells harbour mutations and have osteogenic differentiation capacity, in vivo and in vitro

Central giant cell granulomas of the jaws stromal cells harbour mutations and have osteogenic differentiation capacity, in vivo and in vitro

Angiogenesis in patient‐derived xenografts of odontogenic myxoma

Organoids: approaches and utility in cancer research

Contact Info

Product

Resources

About